Health  Vol.6 No.12 , June 2014
The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia
Abstract: Background: The pathophysiologic mechanisms which lead to cardiovascular (CV) events begin early in childhood. Atherosclerosis is recognized as a process of chronic and dynamic vascular inflammation induced primarily by endothelial dysfunction. Asymmetric dimethylarginine (ADMA) and lipoprotein associated phospholipase A2 (Lp-PLA2) are considered markers of early atherosclerosis and predictors of late complications in adults. Objectives: To establish the relationship between ADMA, Lp-PLA2 and traditional biochemically determined markers in children and adolescents with dyslipidemia. Material and Methods: The study population consisted of 102 children, 57 males/45 females, with a median age of 9.9 years. Seventy-one out of 102 had dyslipidemia (LDL-C levels ≥ 130 mg/dl). Lipid levels were estimated after an overnight fasting. LDL-C concentration was directly measured. ADMA and Lp-PLA2 levels were assessed by enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using STATA for Windows v8.5. Results: ADMA was significantly positively correlated with all TC, LDL-C and non-HDL-C. Even small changes of the ADMA concentration were found to be followed by corresponding alterations in lipid levels. A positive correlation of borderline significance between Lp-PLA2 and LDL-C or non- HDL-C was observed. In addition, ADMA and Lp-PLA2 were significantly correlated. A strong correlation between Lp-PLA2 and dyslipidemia or lipid levels could not be established, probably due to the size and heterogeneity of our sample. Conclusions: A relationship of ADMA and Lp-PLA2 levels with biochemical markers associated with long-term risk of atherosclerosis in children and adolescents is supported. The assessment of these two biomarkers combined may improve CV risk prediction and future management strategies in the pediatric population.
Cite this paper: Klinaki, E. , Soldatou, A. , Marmarinos, A. , Pagoni, A. , Tsentidis, C. , Gourgiotis, D. and Garoufi, A. (2014) The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia. Health, 6, 1440-1446. doi: 10.4236/health.2014.612177.

[1]   (2011) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics, 128, S213-S256.

[2]   Li, S., Chen, W., Srinivasan, S.R., Bond, M.G., Tang, R., Urbina, E.M. and Berenson, G.S. (2003) Childhood Cardiovascular Risk Factors and Carotid Vascular Changes in Adulthood: The Bogalusa Heart Study. JAMA, 290, 2271-2276.

[3]   Hansson, G.K., Libby, P., Schönbeck, U. and Yan, Z.Q. (2002) Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis. Circulation Research, 91, 281-291.

[4]   Szuba, A. and Podgórski, M. (2006) Asymetric Dimethylarginine (ADMA) a Novel Cardiovascular Risk Factor-Evidence from Epidemiological and Prospective Clinical Trials. Pharmacological Reports, 58, 16-20.

[5]   Boger, R.H., Lentz, S.R., Bode-Boger, S.M., Knapp, H.R. and Haynes, W.G. (2001) Elevation of Asymmetrical Dimethylarginine May Mediate Endothelial Dysfunction during Experimental Hyperhomocyst(e)inaemia in Humans. Clinical Science, 100, 161-167.

[6]   Schulze, F.,H. Lenzen, H., Hanefeld, C., Bartling, A., Osterziel, K.J., Goudeva, L., Schmidt-Lucke, C., Kusus, M., Maas, R., Schwedhelm, E., Strodter, D., Simon, B.C., Mugge, A., Daniel, W.G., Tillmanns, H., Maisch, B., Streichert, T. and Boger, R.H. (2006) Asymmetric Dimethylarginine Is an Independent Risk Factor for Coronary Heart Disease: Results from the Multicenter Coronary Artery Risk Determination Investigating the Influence of ADMA Concentration (CARDIAC) Study. American Heart Journal, 152, 493(e1-8).

[7]   Wanby, P., Teerlink, T., Brudin, L., Brattstrom, L.,Nilsson, I., Palmqvist, P. and Carlsson, M. (2006) Asymmetric Dimethylarginine (ADMA) as a Risk Marker for Stroke and TIA in a Swedish Population. Atherosclerosis, 185, 271-277.

[8]   Tain, Y.L. and Huang L.T. (2011) Asymmetric Dimethylarginine: Clinical Applications in Pediatric Medicine: Review Article. Journal of the Formosan Medical Association, 110, 70-77.

[9]   Caia, A., Zheng, D., Qiu, R., Mai, W. and Zhou, Y. (2013) Lipoprotein-Associated Phospholipase A2 (Lp-PLA2): A Novel and Promising Biomarker for Cardiovascular Risks Assessment. Disease Markers, 34, 323-331.

[10]   Packard, C.J., O’Reilly, D.S., Caslake M.J., McMahon, A.D., Ford, I., Cooney, J., Macphee, C.H., Suckling, K.E., Krishna, M., Wilkinson, F., Rumley, A. and Lowe, G.D.O. (2000) Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease. West of Scotland Coronary Prevention Study Group. The New England Journal of Medicine, 343, 1148-1155.

[11]   Corson, M.A., Jones, P.H. and Davidson, M.H. (2008) Review of the Evidence for the Clinical Utility of Lipoprotein-Associated Phospholipase A2 as a Cardiovascular Risk Marker. American Journal of Cardiology, 101, 41F-50F.

[12]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report (2002) Circulation, 106, 3143-3421.

[13]   Davidson, M.H., Corson, M.A., Alberts, M.J., Anderson, J.L., Gorelick, P.B., Jones, P.H., Lerman, A., McConnell, J.P. and Weintraub, H.S. (2008) Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines. American Journal of Cardiology, 101, S51F-S57.

[14]   Ballantyne, C.M., Hoogeveen, R.C., Bang, H., Coresh, J., Folsom, A.R., Heiss, G. and Sharrett, A.R. (2004) Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 109, 837-842.

[15]   Nambi, V., Hoogeveen, R.C., Chambless, L., Hu, Y., Bang, H., Coresh, J., Ni, H., Boerwinkle, E., Mosley, T., Sharrett, R., Folsom, A.R. and Ballantyne, C.M. (2009) Lipoprotein-Associated Phospholipase A2 and High-Sensitivity C-Reactive Protein Improve the Stratification of Is-chemic Stroke Risk In the Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 40, 376-381.

[16]   Hasanoglu, A., Okur, I., Ören, A.C., Biberoglu, G., Oktar, S., Eminoglu, F.T. and Tümer, L. (2011) The Levels of Asymmetric Dimethylarginine, Homocysteine and Carotid Intima-Media Thickness in Hypercholesterolemic Children. The Turkish Journal of Pediatrics, 53, 522-527.

[17]   Jehlicka, P., Stozicky, F., Mayer, O.J., Varvarovská, J., Racek, J., Trefil, L. and Siala, K. (2009) Asymmetric Dimethylarginine and the Effect of Folate Substitution in Children with Familial Hypercholesterolemia and Diabetes Mellitus Type 1. Physiological Research, 58, 179-184.

[18]   Maas, R., Xanthakis, V., Polak, J.F., Schwedhelm, E., Sullivan, L.M., Benndorf, R., Schulze, F., Vasan, R.S., Wolf, P.A., Böger, R.H. and Seshadri, S. (2009) Association of the Endogenous Nitric Oxide Synthase Inhibitor ADMA with Carotid Artery Intimal Media Thickness in the Framingham Heart Study Offspring Cohort. Stroke, 40, 2715-2719.

[19]   Cardounel, A.J., Cui, H., Samouilov, A., Johnson, W., Kearns, P., Tsai, A.L., Berka, V. and Zweier, J.L. (2007) Evidence for the Pathophysiological Role of Endogenous Methylarginines in Regulation of Endothelial NO Production and Vascular Function. The Journal of Biological Chemistry, 282, 879-887.

[20]   Leiper, J., Nandi, M., Torondel, B., Murray-Rust, J., Malaki, M., O’Hara, B., Rossiter, S., Anthony, S., Madhani, M., Selwood, D., Smith, C., Wojciak-Stothard, B., Rudiger, A., Stidwill, R., McDonald, N.Q. and Vallance, P. (2007) Disruption of Methylarginine Metabolism Impairs Vascular Homeostasis. Nature Medicine, 13, 198-203.

[21]   Konishi, H., Sydow, K. and Cooke, J.P. (2007) Dimethylarginine Dimethylaminohydrolase Promotes Endothelial Repair after Vascular Injury. Journal of the American College of Cardiology, 49, 1099-1105.

[22]   Hasegawa, K., Wakino, S., Tatematsu, S., Yoshioka, K., Homma, K., Sugano, N., Kimoto, M., Hayashi, K. and Itoh, H. (2007) Role of Asymmetric Dimethylarginine in Vascular Injury in Transgenic Mice Overexpressing Dimethylarginine Dimethylaminohydrolase 2. Circulation Research, 101, e2-e10.

[23]   Nakata, S., Tsutsui, M., Shimokawa, H., Suda, O., Morishita, T., Shibata, K., Yatera, Y., Sabanai, K., Tanimoto, A., Nagasaki, M., Tasaki, H., Sasaguri, Y., Nakashima, Y., Otsuji, Y. and Yanagihara, N. (2008) Spontaneous Myocardial Infarction in Mice Lacking All Nitric Oxide Synthase Isoforms. Circulation, 117, 2211-2223.

[24]   Meinitzer, A., Seelhorst, U., Wellnitz, B., Halwachs-Baumann, G., Boehm, B.O., Winkelmann, B.R. and Marz, W. (2007) Asymmetrical Dimethylarginine In-dependently Predicts Total and Cardiovascular Mortality in Individuals with Angiographic Coronary Artery Disease (The Ludwigshafen Risk and Cardiovascular Health Study). Clinical Chemistry, 53, 273-283.

[25]   Schnabel, R., Blankenberg, S., Lubos, E., Lackner, K.J., Rupprecht, H.J., Espinola-Klein, C., Jachmann, N., Post, F., Peetz, D., Bickel, C., Cambien, F., Tiret, L. and Munzel, T. (2005) Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients with Coronary Artery Disease: Results from the AtheroGene Study. Circulation Research, 97, e53-e59.

[26]   Leong, T., Zylberstein, D., Graham, I., Lissner, L., Ward, D., Fogarty, J., Bengtsson, C., Björkelund, C. and Thelle, D. (2008) Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women: 24-Year Follow-Up of the Population Study of Women in Gothenburg. Arteriosclerosis, Thrombosis and Vascular Biology, 28, 961-967.

[27]   Tjoelker, L.W., Wilder, C., Eberhardt, C., Stafforini, D.M., Dietsch, G., Schimpf, B., Hooper, S., Le Trong, H., Cousens, L.S., Zimmerman, G.A., Yamada, Y., McIntyre, T.M., Prescott, S.M. and Gray, P.W. (1995) Anti-Inflammatory Properties of a Platelet-Activating Factor Acetylhy-drolase. Nature, 374, 549-553.

[28]   Noto, H., Hara, M., Karasawa, K., Iso-O, N., Satoh, H., Togo, M., Hashimoto, Y., Yamada, Y., Kosaka, T., Kawamura, M., Kimura, S. and Tsukamoto K. (2003) Human Plasma Platelet-Activating Factor Acetylhydrolase Binds to All the Murine Lipoproteins, Conferring Protection Against Oxidative Stress. Arteriosclerosis, Thrombosis and Vascular Biology, 23, 829-835.

[29]   Persson, M., Hedblad, B., Nelson, J.J. and Berglund, G. (2007) Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events among Middle-Aged Nondiabetic Subjects. Arteriosclerosis, Thrombosis and Vascular Biology, 27, 1411-1416.

[30]   Herrmann, J., Mannheim, D., Wohlert, C., Versari, D., Meyer, F.B., McConnell, J.P., Gössl, M., Lerman, L.O. and Lerman, A. (2009) Expression of Lipoprotein-Associated Phospholipase A(2) in Carotid Artery Plaques Predicts Long-Term Cardiac Outcome. European Heart Journal, 30, 2930-2938.

[31]   Ryu S.K., Hutten, B.A., Vissers, M.N., Wiegman, A., Kastelein, J.J. and Tsimikas, S. (2011) Lipoprotein-Associated Phospholipase A2 Mass and Activity in Children with Heterozygous Familial Hypercholesterolemia and Unaffected Siblings: Effect of Pravastatin. Journal of Clinical Lipidology, 5, 50-56.

[32]   Labresh, K.A., Lazorick, S., Ariza, A.J., Furberg, R.D., Whetstone, L., Hobbs, C., de Jesus J., Bender, R.H., Salinas, I.G. and Binns, H.J. (2014) Implementation of the NHLBI Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Rationale and Study Design for Young Hearts, Strong Starts, a Cluster-Randomized Trial Targeting Body Mass Index, Blood Pressure, and Tobacco. Contemporary Clinical Trials, 37, 98-105.